Pacific Edge Limited (“PEB”) – Trading Halt of Securities

NZX Limited
Level 1, NZX Centre
11 Cable Street
PO Box 2959
Wellington 6140
New Zealand
Tel +64 4 472 7599

www.nzx.com


Memorandum

To:
Market Participants
From:
NZX Product Operations
Date:
Tuesday, 29 April 2025
Subject
: Pacific Edge Limited (“PEB”) – Trading Halt of Securities


Message
:
Further to the announcement at 10.27am today regarding the trading halt of Pacific Edge
Limited (“PEB”), attached is the trading halt application, for further information.

Please contact NZX Product Operations on +64 4 496 2853 or productoperations@nzx.com
with any queries.

ENDS

---

29 April 2025



ASX Limited
20 Bridge St
Sydney NSW 2000
Australia

NZ RegCo
11 Cable St
Wellington
New Zealand

Request for trading halt: PACIFIC EDGE LIMITED (ASX Code: PEB, NZX Code: PEB)

We request a trading halt to be applied to our securities: (ISIN: NZPEBE0002S1) under ASX Listing
Rule 17.1 and NZX Listing Rule 9.9.1(a) and set out below details of the request as per the rules of
each of ASX and NZX.

We would like the trading halt to commence from: Immediately

Reasons for the trading halt: Pacific Edge is aware the Centers for Medicare and Medicaid Services
(CMS) has published the draft Gapfill prices for Cxbladder Triage Plus with the median price of
US$1,018.44.
Pacific Edge is currently reviewing the prices and the associated documentation and needs time to
assess the implications of them, consult with its advisers and industry partners, and prepare an
announcement that provides context to investors.
It expects to provide an update to the market, at the latest, before the opening of trading on 30 April
2025.
How long we want the trading halt to last: at the earliest of, the finalisation of the announcement
today (29 April 2025) or the opening of trading on the NZX and ASX on 30 April 2025.

The event we expect to happen that will end the trading halt: The release of a statement to the
market.

Other information necessary to inform the market about the trading halt or that ASX or NZ RegCo
have requested: see the statement below on the information in the market memorandum to be
released in relation to the trading halt.

Information to include in any market memorandum relating to the halt:
Pacific Edge is aware the Centers for Medicare and Medicaid Services (CMS) has published the draft
Gapfill prices for Cxbladder Triage Plus with the median price of US$1,018.44.
Pacific Edge is currently reviewing the published prices and the associated documentation and needs
time to assess the implications of it, consult with its advisers and industry partners, and prepare an
announcement that provides context to investors.

It expects to provide an update to the market at the latest at the opening of trading on 30 April 2025.
In the meantime, the company is not able to make any further comment.
We confirm that we are not aware of any reason why the trading halt should not be granted.

Yours sincerely

Grant Gibson
Chief Financial Officer
Pacific Edge Limited

Trading halt requests should be emailed to NZ RegCo at: issuer@nzregco.com, and to the entity’s
designated Listings Compliance Adviser and the relevant general trading halt email address at ASX:
tradinghaltssydney@asx.com.au, tradinghaltsmelbourne@asx.com.au or
tradinghaltsperth@asx.com.au